The Effect of Nitroglycerin on the Intrauterine Device (IUD) Insertion Experience in Nulliparous Women
Recruitment status was: Recruiting
|Contraception Pain||Drug: Insertion of nitroglycerin ointment Drug: Insertion of placebo ointment|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
|Official Title:||The Effect of Nitroglycerin on the IUD Insertion Experience in Nulliparous Women: a Pilot Study|
- Patient-reported pain at passage of insertion device through cervix, as measured on a 100 mm VAS [ Time Frame: 30-45 minutes after insertion of nitroglycerin ointment ]
- Provider ease with insertion measured on a 100 mm VAS [ Time Frame: 30-45 minutes after insertion of nitroglycerin ointment ]
- Patient-reported pain at tenaculum placement, as measured on a 100 mm VAS [ Time Frame: 30-45 minutes after insertion of nitroglycerin ointment ]
- Vital signs after insertion of nitroglycerin ointment [ Time Frame: 15-60 minutes after insertion of nitroglycerin ointment ]
- Side effects after insertion of nitroglycerin ointment [ Time Frame: 15-60 minutes after insertion of nitroglycerin ointment ]
|Study Start Date:||December 2011|
|Estimated Study Completion Date:||July 2013|
|Estimated Primary Completion Date:||July 2013 (Final data collection date for primary outcome measure)|
|Active Comparator: Active nitroglycerin ointment||
Drug: Insertion of nitroglycerin ointment
Nitroglycerin ointment inserted into the vagina 30-45 minutes prior to IUD insertion
|Placebo Comparator: Placebo ointment||
Drug: Insertion of placebo ointment
Placebo ointment inserted into the vagina 30-45 minutes prior to IUD insertion
Increasing acceptability and use of long acting reversible contraceptive methods like the intrauterine device (IUD) is an important strategy to reduce the risk of unintended pregnancy. Unfortunately, fear of IUD insertion in nulliparous women is common among health care providers and women alike, and this limits IUD use. While many health care providers assume that placement is more difficult in nulliparous women, there is no evidence that the risk of unsuccessful insertion is higher. Women worry about pain with insertion, and their fear is not unfounded as U.S. and international data have shown that nulliparous women report approximately twice as much pain with IUD insertion compared to parous women.
A key difference between nulliparous and multiparous women is the resistance of the cervix. While cervical dilation is uncommonly needed during IUD placement, force is often required to pass the insertion device through the internal os. Although misoprostol and ibuprofen have been studied as ways to improve the IUD insertion experience, neither has proved effective, and misoprostol actually has been shown to increase pain. Therefore, to increase acceptance of this highly effective contraceptive, there is a need to investigate novel, low cost, easily applied and accessible techniques to improve the insertion experience.
Nitric oxide (NO) donors, including nitroglycerin, nitroprusside, isosorbide mononitrate and isosorbide dinitrate, have effects on the animal and human cervix. Both nitroglycerin and isosorbide mononitrate tablets administered vaginally have been shown in RCTs to induce effective cervical ripening with minimal side effects for first trimester abortion compared to placebo. Nitroprusside and isosorbide dinitrate gel given intracervically prior to first trimester abortion also have showed minimal side effects in several RCTs, but with mixed results regarding effectiveness. Additional safety data about NO donors applied topically to skin and mucosal surfaces is well established through the routine use of topical nitroglycerin for treatment of anal fissures.
Although a recent randomized controlled trial (RCT) comparing nitroprusside gel to misoprostol for cervical ripening prior to first trimester surgical abortion found superior cervical dilation in the misoprostol group, there was no significant difference in cervical dilation up to 5 mm. While most studies of abortion are concerned with providing adequate dilation beyond 8 mm, the cervical remodeling that is necessary to help with IUD insertion is much less, as the levonorgestrel intrauterine system (LNG-IUS) inserter is only 4.75 mm in diameter. Since NO donors are smooth muscle relaxants, they are expected to induce cervical ripening without causing uterine cramping, which is the most significant side effect of misoprostol.
Nitroglycerin is inexpensive, stable at room temperature, and readily available in tablet and ointment form, as well as in a dextrose solution for intravenous administration. The ointment form is commonly applied topically for the treatment of anal fissures. We propose the following aims:
- To determine if nitroglycerin ointment applied vaginally 30-45 minutes prior to IUD insertion improves pain among nulliparous women compared to a placebo ointment. Self-reported pain scores on a 100 mm VAS will be assessed at multiple time points during and after the IUD insertion procedure. In addition, overall satisfaction and adverse effects will be evaluated.
- To determine if nitroglycerin ointment applied vaginally 30-45 minutes prior to IUD insertion improves ease of IUD insertion for the provider compared to a placebo ointment. In addition, need for additional dilation, additional pain medicine such as paracervical block, inability to place the IUD, and complications will be tracked.
- To determine if nitroglycerin ointment applied vaginally 30-45 minutes prior to IUD insertion is safe and well tolerated. Side effects related to treatment with nitroglycerin ointment or placebo will be compared. Blood pressure will be measured at multiple time points.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01490073
|United States, Oregon|
|Planned Parenthood Columbia Willamette||Not yet recruiting|
|Portland, Oregon, United States, 97212|
|Contact: Brenna Monahan email@example.com|
|Oregon Health & Science University||Recruiting|
|Portland, Oregon, United States, 97239|
|Contact: Elizabeth Micks, MD 503-494-9556|
|Principal Investigator: Elizabeth Micks, MD|
|Principal Investigator: Paula Bednarek, MD, MPH|